Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.

Archives of gynecology and obstetrics - 1 Jan 2024

Cimino Giuseppe, Sorrenti Sara, Murciano Manuel, Galoppi Paola, Ascenzioni Fiorentina, Botta Bruno, Brunelli Roberto

Abstract excerpt

INTRODUCTION: Management of cystic fibrosis has recently stepped forward with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, although data on potential adverse effects are lacking for many categories of patients, such as pregnant women. METHODS: We report one of the first reports on the outcome of pregnancy in a woman treated with Elexacaftor/Tezacaftor/Ivacaftor during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Infant, Newborn

Share to Mutation

Share to Pregnancy

Source

Identifiers

PMID: 36907900
DOI: 10.1007/s00404-023-06962-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.PMID 36907900Read ↗

Use of CFTR modulators in special populations, part 1: Pregnancy and lactation.Semantic proximity Read ↗

"Shifting sands in cystic fibrosis": impacts of CFTR modulators on reproductive health in people with cystic fibrosis and challenges related to in utero exposure.Semantic proximity Read ↗

Unplanned pregnancies following the introduction of elexacaftor/tezacaftor/ivacaftor therapy in women with cystic fibrosis.Semantic proximity Read ↗

CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful caseSemantic proximity Read ↗

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancySemantic proximity Read ↗

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialSemantic proximity Read ↗

Pregnancy in cystic fibrosis: Review of the literature and expert recommendationsSemantic proximity Read ↗

Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control StudySemantic proximity Read ↗

Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?Semantic proximity Read ↗

Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.Semantic proximity Read ↗

Elexacaftor/Ivacaftor/Tezacaftor: First Approval.Semantic proximity Read ↗

CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic FibrosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.